MUMBAI/NEW DELHI Shares in the Indian units of U.S.-based drugmakers Pfizer (PFE.N) (PFIZ.NS) and Abbott Laboratories (ABT.N) (ABOT.NS) fell as much as 5 percent on Monday after authorities imposed a ban on their codeine-based cough syrups, saying they posed a health risk.
Pfizer’s India unit said in a statement it had stopped selling its Corex cough syrup that contains codeine, a narcotic. Abbott, which sells the syrup under the Phensedyl brand name, did not respond to a request for comment.
The medicines, which are a combination of chlopheniramine maleate and codeine, were among 344 drug combinations India banned over the weekend after a government panel of experts found they had “no therapeutic justification.”
The banned combinations had entered the market over the years based on approval from regulators of individual states, rather the central government, as legally required.
The decision on Corex is likely to hit Pfizer’s revenue and profit. The brand brought in sales of about 1.76 billion rupees ($26.29 million) in the nine months ended December 2015, the company said in a statement.
Abbott’s Phensedyl accounts for about a third of the Indian cough syrup market, and its sales are estimated to make up more than 3 percent of the company’s $1 billion India revenue.
Shares in Pfizer Ltd fell as much as 5.2 percent in early Indian trade on Monday, while Abbott India Ltd’s shares fell nearly 3 percent. The broader market .NSEI was down 0.76 percent.
Reuters reported last October that Indian regulators were privately pressuring drug firms to better police the selling of popular codeine-based cough syrups to tackle smuggling and addiction.
Doctors and health officials interviewed then had said that while drug abuse was a concern, the medicine was an effective cough suppressant.
Pfizer said it believed Corex had a “well-established efficacy and safety profile in India for more than 30 years” and that it was “exploring all possible options at its disposal.”
The International Narcotics Control Board has billed the abuse of medicines containing narcotics and their smuggling from India among the “greatest drug-related challenges” facing South Asia.
Akun Sabharwal, the drugs controller for the southern state of Telangana, welcomed the ban on codeine-based cough syrups. His state last year detected an “illegal diversion” of Phensedyl worth 570 million rupees, he said.
“We are happy this will stop the misuse of the medicine,” Sabharwal told Reuters.
($1 = 66.9550 Indian rupees)
(Reporting by Zeba Siddiqui in MUMBAI and Aditya Kalra in NEW DELHI; Editing by Paritosh Bansal and Kim Coghill)